Scarica l'app Stockscreener
1.68
8.39%
0.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HUMA Giù?
Forum
Previsione
Humacyte Inc Borsa (HUMA) Ultime notizie
Press Release Distribution & PR Platform - ACCESS Newswire
Humacyte responds to recent attacks By Investing.com - Investing.com Canada
Humacyte Challenges FDA Petition Amidst Controversy - TipRanks
Humacyte responds to recent attacks - Investing.com
Humacyte’s Promising Market Penetration and Revenue Projections Justify Buy Rating - TipRanks
Humacyte chief commercial officer purchases $9,999 in common stock - Investing.com Australia
Humacyte, Inc. (HUMA) Increases Despite Market Slip: Here's What You Need to Know - MSN
Humacyte chief commercial officer purchases $9,999 in common stock By Investing.com - Investing.com India
Humacyte CFO Dale Sander buys $30,600 in company stock - Investing.com Australia
Humacyte CFO Dale Sander buys $30,600 in company stock By Investing.com - Investing.com South Africa
Humacyte’s chief medical officer acquires $11,625 in common stock By Investing.com - Investing.com South Africa
Humacyte’s chief medical officer acquires $11,625 in common stock - Investing.com Australia
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Shareholders - ACCESS Newswire
Small-Caps Explode Higher As Tariff Fears Ease: Humacyte, Forward Air, FormFactor Top Russell 2000 - Benzinga
Investigation announced for Investors who hold shares of Humacyte, Inc. (NASDAQ: HUMA) - openPR.com
Humacyte director Charles Green acquires $7,740 in stock - Investing.com Australia
Humacyte director Michael Constantino buys $20,160 in stock By Investing.com - Investing.com South Africa
Humacyte director Kathleen Sebelius acquires $66,000 in common stock By Investing.com - Investing.com South Africa
Humacyte director Michael Constantino buys $20,160 in stock - Investing.com
Humacyte director Charles Green acquires $7,740 in stock By Investing.com - Investing.com India
Humacyte director Kathleen Sebelius acquires $66,000 in common stock - Investing.com
Humacyte Executives Increase Holdings with Recent Purchases - TradingView
Humacyte, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - ACCESS Newswire
Humacyte, Inc. (HUMA) Stock Moves -0.68%: What You Should Know - MSN
Humacyte’s $50 Million Common Stock Offering - Global Legal Chronicle
HUMA stock touches 52-week low at $1.3 amid market challenges By Investing.com - Investing.com South Africa
Investors who lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class ActionHUMA - ACCESS Newswire
Shareholders that Lost Money on Humacyte, Inc. (HUMA) Should Contact Levi & Korsinsky about Pending Class ActionHUMA - ACCESS Newswire
Shareholders of Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - ACCESS Newswire
Humacyte, Inc. (NASDAQ:HUMA) Q4 2024 Earnings Call Transcript - Insider Monkey
Humacyte’s Earnings Call: Balancing Achievements and Challenges - TipRanks
Humacyte Stock (HUMA) Hits Record Low Post Q4 Results Despite FDA Nod for Vascular Trauma Treatment - markets.businessinsider.com
symbol__ Stock Quote Price and Forecast - CNN
Benchmark maintains Buy rating, $17 target on Humacyte stock By Investing.com - Investing.com UK
Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025HUMA - ACCESS Newswire
Humacyte Inc. Warrant (HUMAW) reports earnings - qz.com
Humacyte down following quarterly results, hits record low - MSN
Shareholders that lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class ActionHUMA - ACCESS Newswire
Humacyte Stock Continues Slide Despite Lower Than Expected Q4 Loss – But Retail Gets More Bullish - MSN
Humacyte price target lowered to $8 from $10 at BTIG - Yahoo Finance
Humacyte’s Symvess Gains FDA Approval and Launches - TipRanks
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):